Aditya Birla Sunlife Life Pharma & Healthcare IDCW Payout Direct Plan
SIP amount
Min. ₹100
Lumpsum amount
Min. ₹1,000

Aditya Birla Sunlife Life Pharma & Healthcare IDCW Payout Direct Plan

NAV
₹22.5700
-0.66%
(2 Feb)
AUM
837 Cr
TER
1.02%
Risk
Very High Risk
Insights
Net Asset Value (NAV) is below its 200 days moving average
Total Expense Ratio (TER) is in the top 25% of comparable funds
In beta. Send feedback here.
Compare with other fund
1Y
+22.1%
+22.1%
+19.2%
+19.2%
+1.1%
3Y
+33.7%
+33.7%
+32.0%
+32.0%
+22.3%
5Y
+30.3%
+30.3%
+32.0%
+32.0%
+14.2%
ALL
+16.8%
+16.8%
+12.4%
+12.4%
+19.3%
VOL
20.1%
20.1%
20.0%
20.0%
16.6%
TER
0.9%
0.9%
0.8%
0.8%
1.0%
AUM
₹1,449 Cr
₹1,449 Cr
₹5,817 Cr
₹5,817 Cr
₹837 Cr
INFO
0.84
0.84
0.62
0.62
1.16
Past performance
Past performance is no guarantee of future returns.
Had you invested
Over the last
1Y
3Y
ALL
Your returns would have been
Aditya Birla Sunlife Life Pharma & Healthcare IDCW Payout (DP)
₹1,00,00,00,000
14.0%
Fixed deposit
₹40,00,00,000
6.0%
Bank savings
₹40,00,00,000
3.0%
See fund holdings as of 31st Dec
Top holdings
Sun Pharmaceuticals Industries Ltd
13.5%
Apollo Hospitals Enterprise Ltd
7.1%
Cipla Ltd
6.1%
Torrent Pharmaceuticals Ltd
4.7%
J.B. Chemicals & Pharmaceuticals Ltd
4.5%
Abbott India Ltd
4.5%
Ajanta Pharma Ltd
4.3%
Aurobindo Pharma Ltd
4.1%
Fortis Healthcare Ltd
4.0%
Lupin Ltd
3.9%
Top industry exposure
Healthcare
97.9%
Basic Materials
0.9%
Other information
Minimum SIP
₹100
Minimum lumpsum
₹1,000
Additional lumpsum
₹1,000
Portfolio turnover
32%
Lock-in period
-
Exit load
• 1% for redemption within 30 days
Fund objective
The scheme provides long term capital appreciation by investing in equity/equity related instruments of the companies in the Pharmaceuticals, Healthcare and Allied sectors in India. The Scheme does not guarantee/indicate any returns. There can be no assurance that the schemes’ objectives will be achieved.
Fund manager(s)
Dhaval Shah

FAQs